@misc{indiciaec708e6f4cf61,
  title = {CETSA MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target},
  author = {Friman, T. and Chernobrovkin, A. and Martinez Molina, D. and Arnold, L. H.},
  year = {2020},
  doi = {10.1101/2020.07.19.210492},
  url = {https://www.biorxiv.org/content/10.1101/2020.07.19.210492v1},
  note = {Source identifier: 10.1101/2020.07.19.210492}
}